Validity of administrative codes associated with cirrhosis in Sweden-Reference-Cited by-同舟云学术

Validity of administrative codes associated with cirrhosis in Sweden

Published:2020-09-22 Issue:10 Volume:55 Page:1205-1210
ISSN:0036-5521
Container-title:Scandinavian Journal of Gastroenterology
language:en
Short-container-title:Scandinavian Journal of Gastroenterology

Author:

Bengtsson Bonnie¹²^ORCID,Askling Johan³⁴^ORCID,Ludvigsson Jonas F.⁵⁶⁷⁸^ORCID,Hagström Hannes¹²⁴^ORCID

Affiliation:

1. Division of Hepatology, Department of Upper GI, Karolinska University Hospital, Stockholm, Sweden

2. Unit of Gastroenterology and Rheumatology, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden

3. Rheumatology, Theme Inflammation and Infection, Karolinska University Hospital, Stockholm, Sweden

4. Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden

5. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

6. Department of Pediatrics, Örebro University Hospital, Örebro, Sweden

7. Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, UK

8. Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA

Publisher

Informa UK Limited

Subject

Gastroenterology

Link

https://www.tandfonline.com/doi/pdf/10.1080/00365521.2020.1820566

Reference22 articles.

1. Burden of liver diseases in the world

2. World Health Organization. International Classification of Diseases (ICD) Information Sheet [internet] Geneva: World Health Organization; 2020 [cited 2020 May 26]. Available from: https://www.who.int/classifications/icd/factsheet/en/

3. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study

4. Use of Administrative Claims Data for Identifying Patients with Cirrhosis

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Socioeconomic factors associated with the presence of and outcomes in metabolic dysfunction‐associated steatotic liver disease;Liver International;2024-09-02

2. Association between longitudinal biomarkers and major adverse liver outcomes in patients with non-cirrhotic metabolic dysfunction–associated steatotic liver disease;Hepatology;2024-08-07

3. Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in Patients With Cirrhosis and Atrial Fibrillation;Annals of Internal Medicine;2024-08

4. Metabolic dysfunction‐associated steatotic liver disease has become the most common cause of hepatocellular carcinoma in Sweden: A nationwide cohort study;International Journal of Cancer;2024-07-17

5. Substitutions of saturated fat intakes with other macronutrients and foods and risk of NAFLD cirrhosis and all-cause hepatocellular carcinoma: a prospective cohort study;The American Journal of Clinical Nutrition;2024-07